Chaitanya Ravi, MD
Internal Medicine · Baltimore, MDNPI 1376504027
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,305 of the $35,727 with a category attached, or 62.4%. 31 manufacturers reported payments, led by Johnson & Johnson at 32.5% of the total. Reporting peaked in 2019 at $21,813 and has fallen 97.4% since, to $557 in 2025. Among internal medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 310 payments — averaging $115.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$12K
- Pfizer$9K
- AbbVie$7K
- E.r. Squibb & Sons, L.L.C.$4K
- Novo Nordisk$711
- Lilly USA, LLC$588
- plus $2K from 25 others
Across 10 payments — averaging $32,319 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- American Regent$323K
What the payments were for
- Consulting fees$4,07511%
- Speaking & faculty fees$22,30562%
- Travel & lodging$1,7645%
- Food & beverage$7,47721%
- Education$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 41 | $11,625 |
| Pfizer | 28 | $9,074 |
| AbbVie(2 entities) | 72 | $7,091 |
| E.r. Squibb & Sons, L.L.C. | 13 | $4,327 |
| Novo Nordisk | 27 | $711 |
| Lilly USA, LLC | 35 | $588 |
| Amgen(2 entities) | 14 | $445 |
| Exact Sciences | 15 | $357 |
| Astellas Pharma US Inc | 11 | $270 |
| Novartis | 8 | $250 |
| Sunovion Pharmaceuticals Inc. | 4 | $175 |
| AstraZeneca | 7 | $137 |
| GSK | 6 | $121 |
| Bayer | 5 | $106 |
| Merck | 4 | $73 |
| Abbott | 3 | $41 |
| Eisai Inc. | 1 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Dexcom, Inc. | 1 | $26 |
| Medtronic | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $20 |
| UCB, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Gilead | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,727 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $78,977 |
| MounjaroTirzepatide | 34 | $42,858 |
| EliquisApixaban | 47 | $41,676 |
| FarxigaDapagliflozin Propanediol | 49 | $38,110 |
| LinzessLinaclotide | 40 | $33,266 |
| TrulicityDulaglutide | 27 | $30,539 |
| JardianceEmpagliflozin | 33 | $25,381 |
| RybelsusSemaglutide | 14 | $14,977 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $13,623 |
| Warfarin Sodium | 897 | $10,835 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $9,202 |
| MyrbetriqMirabegron | 13 | $8,843 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $8,513 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,672 |
| Atorvastatin Calcium | 274 | $4,505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $711 | $93,95481 claims |
| Lilly USA, LLCMounjaro, Trulicity | $588 | $73,39761 claims |
| PfizerEliquis | $9,074 | $41,67647 claims |
| AstraZenecaFarxiga | $137 | $38,11049 claims |
| AbbVieLinzess | $7,091 | $33,26640 claims |
| MerckJanumet | $73 | $13,62313 claims |
| Astellas Pharma US IncMyrbetriq | $270 | $8,84313 claims |
| GSKTrelegy Ellipta | $121 | $8,51315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Baltimore
- Param DedhiaBaltimore$636K
- Shawn DhillonBaltimore$227K
- Jeremy SugarmanBaltimore$210K
- Charles FlexnerBaltimore$133K
- Kristen MarroneBaltimore$97K
- Ana-Maria OrbaiBaltimore$89K
- Mark YarchoanBaltimore$89K
- David Muniz PedrogoBaltimore$82K
- Julie PaikBaltimore$76K
- Allison AgwuBaltimore$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.